[{"id":"de85007a-8a96-4d92-b410-2aebe8f02c18","acronym":"","url":"https://clinicaltrials.gov/study/NCT06007924","created_at":"2023-08-23T15:11:08.435Z","updated_at":"2025-02-25T15:13:43.406Z","phase":"Phase 2","brief_title":"A Study of Avutometinib and Defactinib in People With Thyroid Cancer","source_id_and_acronym":"NCT06007924","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF • ALK • RET • NF1 • NTRK","pipe":" | ","alterations":" BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement","tags":["BRAF • ALK • RET • NF1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/16/2023","start_date":" 08/16/2023","primary_txt":" Primary completion: 08/16/2027","primary_completion_date":" 08/16/2027","study_txt":" Completion: 08/16/2027","study_completion_date":" 08/16/2027","last_update_posted":"2025-02-13"},{"id":"152d28df-5166-4844-8189-63865407b89e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05954546","created_at":"2023-07-20T23:10:56.186Z","updated_at":"2025-02-25T16:46:55.104Z","phase":"","brief_title":"A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings","source_id_and_acronym":"NCT05954546","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Completed","enrollment":" Enrollment 275","initiation":"Initiation: 07/21/2023","start_date":" 07/21/2023","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2025-02-05"},{"id":"d0abf381-bbfa-4b21-bbe7-740e5caad62b","acronym":"BEAVER","url":"https://clinicaltrials.gov/study/NCT03839342","created_at":"2021-01-18T18:57:15.711Z","updated_at":"2025-02-25T16:59:56.947Z","phase":"Phase 2","brief_title":"Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations","source_id_and_acronym":"NCT03839342 - BEAVER","lead_sponsor":"University Health Network, Toronto","biomarkers":" BRAF • KIAA1549","pipe":" | ","alterations":" BRAF mutation • BRAF V600K • BRAF fusion","tags":["BRAF • KIAA1549"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600K • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 06/07/2019","start_date":" 06/07/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"},{"id":"c140a8b8-ac68-4df9-988d-ebe6e54e87b6","acronym":"DETERMINE","url":"https://clinicaltrials.gov/study/NCT06194929","created_at":"2024-01-08T19:20:11.355Z","updated_at":"2025-02-25T17:32:44.459Z","phase":"Phase 1/2","brief_title":"Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma","source_id_and_acronym":"NCT06194929 - DETERMINE","lead_sponsor":"University of Utah","biomarkers":" NF1 • RAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation","tags":["NF1 • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Braftovi (encorafenib) • Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 03/07/2024","start_date":" 03/07/2024","primary_txt":" Primary completion: 01/15/2028","primary_completion_date":" 01/15/2028","study_txt":" Completion: 01/15/2030","study_completion_date":" 01/15/2030","last_update_posted":"2025-01-30"},{"id":"7ae39bae-f74c-4bd9-bb9c-b0ac08141f45","acronym":"","url":"https://clinicaltrials.gov/study/NCT04892017","created_at":"2021-05-19T15:52:38.986Z","updated_at":"2024-07-02T16:34:26.607Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors","source_id_and_acronym":"NCT04892017","lead_sponsor":"Deciphera Pharmaceuticals LLC","biomarkers":" KRAS • BRAF • NRAS • NF1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • KRAS G12C • NRAS mutation • BRAF V600 • BRAF V600K • NF1 mutation • KRAS G12","tags":["KRAS • BRAF • NRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • KRAS G12C • NRAS mutation • BRAF V600 • BRAF V600K • NF1 mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Lumakras (sotorasib) • Mektovi (binimetinib) • inlexisertib (DCC-3116)"],"overall_status":"Recruiting","enrollment":" Enrollment 173","initiation":"Initiation: 06/15/2021","start_date":" 06/15/2021","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2024-06-13"},{"id":"92435528-4415-4d93-8e63-2a53a10bdf30","acronym":"","url":"https://clinicaltrials.gov/study/NCT04250545","created_at":"2021-01-18T20:39:21.304Z","updated_at":"2024-07-02T16:34:58.880Z","phase":"Phase 1","brief_title":"Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04250545","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • ALK • ROS1 • KEAP1 • NFE2L2","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • BRAF V600K • KEAP1 mutation • NFE2L2 mutation","tags":["KRAS • BRAF • ALK • ROS1 • KEAP1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • BRAF V600K • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapanisertib (CB-228) • telaglenastat (CB-839)"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 10/26/2020","start_date":" 10/26/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"2b720bdb-c868-4015-be63-be0574eeacf1","acronym":"PORTSIDE","url":"https://clinicaltrials.gov/study/NCT05926960","created_at":"2023-07-03T17:09:32.633Z","updated_at":"2024-07-02T16:34:59.560Z","phase":"Phase 2","brief_title":"A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma","source_id_and_acronym":"NCT05926960 - PORTSIDE","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 06/13/2023","start_date":" 06/13/2023","primary_txt":" Primary completion: 05/23/2025","primary_completion_date":" 05/23/2025","study_txt":" Completion: 05/23/2027","study_completion_date":" 05/23/2027","last_update_posted":"2024-06-03"},{"id":"db82afaa-1da0-4791-94e2-92a3b0bc6788","acronym":"BECOME-MB","url":"https://clinicaltrials.gov/study/NCT04074096","created_at":"2021-01-18T19:57:18.686Z","updated_at":"2025-02-25T16:09:27.668Z","phase":"Phase 2","brief_title":"Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis","source_id_and_acronym":"NCT04074096 - BECOME-MB","lead_sponsor":"UNICANCER","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/05/2022","start_date":" 09/05/2022","primary_txt":" Primary completion: 04/15/2025","primary_completion_date":" 04/15/2025","study_txt":" Completion: 04/15/2029","study_completion_date":" 04/15/2029","last_update_posted":"2024-06-03"},{"id":"a4fa2c9b-d0d8-45aa-8666-8374568e8a92","acronym":"EBIN","url":"https://clinicaltrials.gov/study/NCT03235245","created_at":"2021-01-18T15:59:13.644Z","updated_at":"2024-07-02T16:35:00.361Z","phase":"Phase 2","brief_title":"Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib","source_id_and_acronym":"NCT03235245 - EBIN","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 271","initiation":"Initiation: 10/30/2018","start_date":" 10/30/2018","primary_txt":" Primary completion: 10/24/2023","primary_completion_date":" 10/24/2023","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-05-29"},{"id":"7f2b6ae3-35ab-4144-9fdd-b8dfede43457","acronym":"STARBOARD","url":"https://clinicaltrials.gov/study/NCT04657991","created_at":"2021-01-19T20:41:58.558Z","updated_at":"2024-07-02T16:35:03.047Z","phase":"Phase 3","brief_title":"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma","source_id_and_acronym":"NCT04657991 - STARBOARD","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 189","initiation":"Initiation: 01/15/2021","start_date":" 01/15/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-05-17"},{"id":"cfc2985f-51c4-4ab9-8232-962b73ff7481","acronym":"NCI-2013-02103","url":"https://clinicaltrials.gov/study/NCT01989585","created_at":"2021-01-18T09:04:22.279Z","updated_at":"2024-07-02T16:35:03.325Z","phase":"Phase 1/2","brief_title":"Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma","source_id_and_acronym":"NCT01989585 - NCI-2013-02103","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • BCL2","pipe":" | ","alterations":" BRAF V600E • BRAF mutation • BRAF V600 • PTEN mutation • BRAF V600K","tags":["PTEN • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF mutation • BRAF V600 • PTEN mutation • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • navitoclax (ABT 263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/24/2014","start_date":" 03/24/2014","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-16"},{"id":"fba96961-c2b5-441c-84a0-51876bc0c2d2","acronym":"COLUMBUS","url":"https://clinicaltrials.gov/study/NCT01909453","created_at":"2021-01-17T17:33:15.479Z","updated_at":"2024-07-02T16:35:07.254Z","phase":"Phase 3","brief_title":"Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma","source_id_and_acronym":"NCT01909453 - COLUMBUS","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 921","initiation":"Initiation: 09/16/2013","start_date":" 09/16/2013","primary_txt":" Primary completion: 11/09/2016","primary_completion_date":" 11/09/2016","study_txt":" Completion: 07/15/2024","study_completion_date":" 07/15/2024","last_update_posted":"2024-04-26"},{"id":"e4c18b05-2e33-449c-8b23-428803a321f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03239145","created_at":"2021-01-18T16:00:23.405Z","updated_at":"2025-02-25T16:06:38.668Z","phase":"Phase 1","brief_title":"Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT03239145","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • trebananib (AMG 386)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 08/31/2017","start_date":" 08/31/2017","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2024-03-20"},{"id":"89ba88cd-80a1-431f-9a1a-3255d4d165a7","acronym":"NCI-2021-11063","url":"https://clinicaltrials.gov/study/NCT05176470","created_at":"2022-01-04T13:53:34.324Z","updated_at":"2024-07-02T16:35:15.802Z","phase":"Phase 1","brief_title":"Neoadj Admin Autologous Tumor Infiltrating Lymphocytes \u0026 Pembrolizumab for Treatment of Adv Melanoma Patients","source_id_and_acronym":"NCT05176470 - NCI-2021-11063","lead_sponsor":"Richard Wu","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • Amtagvi (lifileucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-07"},{"id":"92b543b8-0666-45b8-8525-786af02d2693","acronym":"","url":"https://clinicaltrials.gov/study/NCT04418167","created_at":"2021-01-18T21:17:40.725Z","updated_at":"2024-07-02T16:35:20.996Z","phase":"Phase 1","brief_title":"JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations","source_id_and_acronym":"NCT04418167","lead_sponsor":"JS InnoPharm, LLC","biomarkers":" MAP2K1 • NF1 • RASA1","pipe":" | ","alterations":" BRAF V600E • BRAF V600K","tags":["MAP2K1 • NF1 • RASA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tafinlar (dabrafenib) • JSI-1187"],"overall_status":"Suspended","enrollment":" Enrollment 71","initiation":"Initiation: 06/18/2020","start_date":" 06/18/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/17/2024","study_completion_date":" 12/17/2024","last_update_posted":"2024-02-02"},{"id":"4e8d1c5a-aa92-47e5-9dde-7cd5c8707088","acronym":"","url":"https://clinicaltrials.gov/study/NCT05756556","created_at":"2023-03-06T15:01:55.600Z","updated_at":"2024-07-02T16:35:21.279Z","phase":"Phase 2","brief_title":"T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma","source_id_and_acronym":"NCT05756556","lead_sponsor":"ImmVira Pharma Co. Ltd","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K • RAS mutation • BRAF V600E + BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K • RAS mutation • BRAF V600E + BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib) • T3011"],"overall_status":"Suspended","enrollment":" Enrollment 68","initiation":"Initiation: 06/30/2024","start_date":" 06/30/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-02-01"},{"id":"510051c8-1213-4a1c-9186-6194ed798450","acronym":"CELEBRATE","url":"https://clinicaltrials.gov/study/NCT04720768","created_at":"2024-01-04T16:17:19.037Z","updated_at":"2024-07-02T16:35:24.560Z","phase":"Phase 1/2","brief_title":"Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE","source_id_and_acronym":"NCT04720768 - CELEBRATE","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" CDK4","pipe":" | ","alterations":" BRAF V600E • BRAF mutation • BRAF V600 • BRAF V600K","tags":["CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF mutation • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 06/04/2020","start_date":" 06/04/2020","primary_txt":" Primary completion: 12/04/2024","primary_completion_date":" 12/04/2024","study_txt":" Completion: 12/04/2024","study_completion_date":" 12/04/2024","last_update_posted":"2024-01-04"},{"id":"1197bf98-e886-4933-a7d3-f8de938ec04d","acronym":"COLUMBUS-AD","url":"https://clinicaltrials.gov/study/NCT05270044","created_at":"2022-03-08T16:52:28.598Z","updated_at":"2024-07-02T16:35:28.320Z","phase":"Phase 3","brief_title":"Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.","source_id_and_acronym":"NCT05270044 - COLUMBUS-AD","lead_sponsor":"Pierre Fabre Medicament","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 815","initiation":"Initiation: 05/02/2022","start_date":" 05/02/2022","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 05/02/2035","study_completion_date":" 05/02/2035","last_update_posted":"2023-11-22"},{"id":"657a150b-5f41-44b4-ab84-352d511b0114","acronym":"","url":"https://clinicaltrials.gov/study/NCT01325441","created_at":"2021-01-18T05:23:55.341Z","updated_at":"2024-07-02T16:35:29.056Z","phase":"Phase 1/2","brief_title":"A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies","source_id_and_acronym":"NCT01325441","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" BRAF • ER • ALK • PGR","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • HER-2 negative • BRAF V600 • ALK positive • BRAF V600K • BRAF wild-type • ER negative • EGFR positive • PGR negative","tags":["BRAF • ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • HER-2 negative • BRAF V600 • ALK positive • BRAF V600K • BRAF wild-type • ER negative • EGFR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • albumin-bound paclitaxel • napabucasin (BBI608)"],"overall_status":"Completed","enrollment":" Enrollment 565","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2023-11-15"},{"id":"c84efa33-90ef-4b31-bf1b-b06d07e79cb4","acronym":"EBRAIN-MEL","url":"https://clinicaltrials.gov/study/NCT03898908","created_at":"2021-01-18T19:12:00.786Z","updated_at":"2024-07-02T16:35:42.700Z","phase":"Phase 2","brief_title":"Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain","source_id_and_acronym":"NCT03898908 - EBRAIN-MEL","lead_sponsor":"Grupo Español Multidisciplinar de Melanoma","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 07/18/2019","start_date":" 07/18/2019","primary_txt":" Primary completion: 10/10/2022","primary_completion_date":" 10/10/2022","study_txt":" Completion: 10/10/2023","study_completion_date":" 10/10/2023","last_update_posted":"2023-07-18"},{"id":"8790b5b4-a08c-451b-a3e9-b8bd7f87117b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04527549","created_at":"2021-01-18T21:40:53.974Z","updated_at":"2024-07-02T16:35:45.270Z","phase":"Phase 2","brief_title":"Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma","source_id_and_acronym":"NCT04527549","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" IL2","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • hydroxychloroquine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2023-06-22"},{"id":"d78d9e2f-3c77-49ca-aca9-de0c64463134","acronym":"","url":"https://clinicaltrials.gov/study/NCT03864042","created_at":"2021-01-18T19:03:40.345Z","updated_at":"2024-07-02T16:35:46.191Z","phase":"Phase 1","brief_title":"Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors","source_id_and_acronym":"NCT03864042","lead_sponsor":"Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib) • modafinil • omeprazole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 01/02/2018","start_date":" 01/02/2018","primary_txt":" Primary completion: 07/11/2022","primary_completion_date":" 07/11/2022","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2023-06-08"},{"id":"a9fb190d-5040-4b41-93e3-ee7c0f5f1fc3","acronym":"MK3475-C01","url":"https://clinicaltrials.gov/study/NCT05304546","created_at":"2022-03-31T17:52:51.205Z","updated_at":"2024-07-02T16:35:46.583Z","phase":"Phase 2","brief_title":"Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma","source_id_and_acronym":"NCT05304546 - MK3475-C01","lead_sponsor":"Dr. Ronnie Shapira","biomarkers":" MYC • CD8 • CTLA4 • ACAT1","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["MYC • CD8 • CTLA4 • ACAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2023-06-05"},{"id":"2e9c47f2-4cd8-4fc4-bb34-ab7a99f8abdd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05263453","created_at":"2022-03-02T16:52:42.865Z","updated_at":"2024-07-02T16:35:46.842Z","phase":"Phase 2","brief_title":"HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation","source_id_and_acronym":"NCT05263453","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Kolupin (tunlametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 09/06/2021","start_date":" 09/06/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-05-31"}]